The CRISPR/Cas9 system has emerged as a powerful tool for precise genome editing, allowing for the deletion of genes, generation of point mutations, and addition of tags to endogenous genes. We employed an efficient CRISPR/Cas9 technique in Leishmania major to assess its efficiency in editing a kDNA-associated gene, universal minicircle sequence binding protein (UMSBP), which is involved in mitochondrial respiration and kinetoplast division. We generated UMSBP C-tagged and UMSBP single knockout L. major (LmUMSBP+/−) parasites using the CRISPR/Cas9 toolkit. C-tagged parasite were confirmed by PCR, flow cytometry and Western blot analyses. Gene expression of mitochondrial redox regulating enzymes, tryparedoxin peroxidase (TXNPx) and trypanothione synthetase (TryS), were analysed by real-time RT-PCR. Growth rate of promastigotes in culture and infectivity rate in macrophages were analysed in vitro. Mice were immunized by LmUMSBP+/− mutant strain and lesion size and parasite burden were measured upon challenge with live wild type (WT) L. major. Cytokines were titrated on supernatant of lymph nodes cell culture by sandwich ELISA. Complete UMSBP deletion (LmUMSBP-/- null mutant) impaired promastigote survival, suggesting its essential role in parasite fitness. Despite this, we were able to produce attenuated LmUMSBP+/- parasites, which showed significant reduced growth in culture (P<0.05), increase in apoptosis (P<0.05) and downregulation of TXNPx and TryS gene expressions during growth of promastigotes compared to WT L. major. LmUMSBP+/- mutant strains did not cause ulcerative lesions in susceptible BALB/c mouse model. Furthermore, immunization of mice with LmUMSBP+/- parasites elicited a Th1 immune response with significantly high IFN-γ and low IL4 production in cell culture (P<0.001) associated with partial protection against L. major WT challenge, as evidenced by reduced parasite burden and lesion development in BALB/c mice. Our findings demonstrate the potential of CRISPR/Cas9-edited LmUMSBP+/- parasites as live attenuated vaccine candidate against Leishmania infection.